Drug Discovery and Molecular Docking (DDMD)
ISSN: 3107-6688 | Vol. 02, Issue-02, May-Aug., 2026 | pp. 124-139

Sickle Cell Disease, Thalassemia, Leukemia, Lymphoma, Myelodysplastic Syndromes, Hemophilia, Anemia, Eosinophilia, Thrombocytopenia: Pathogens, Pathophysiology, Etiology, Epidemiology, AI, ML Modeling, 3D Fingerprinting, Hematologic Disorders

Yash Srivastav[1*], Anubha Dhuriya[2], Stuti Verma[2], Rajeev Kumar[2], Shivani Singh[1]

[1]D.K.R.R Pharmacy College, Amberpur, Sitapur, Uttar Pradesh, India

[2]Aryakul College of Pharmacy and Research, Sitapur, Uttar Pradesh, India. 261303

***Corresponding Author E-mail: yashsrv.108@gmail.com**

Abstract:

Hematologic disorders refer to a broad range of both genetic and non-genetic disorders involving the red blood cells, white blood cells, platelets, coagulation factors, and bone marrow, such as sickle cell disease (SCD), thalassemia, leukemia, lymphoma, myelodysplastic disorders, hemophilia, anemia, eosinophilia, and thrombocytopenia. The review highlights contemporary evidence in humans about the etiology, pathophysiology, epidemiology, diagnosis, and computational implications of these disorders. Special attention is paid to the application of artificial intelligence (AI), machine learning (ML), digital pathology, genomics, and multimodal data fusion to their diagnostics and prognosis. The review further describes three-dimensional (3D) morphologic and molecular fingerprinting as an alternative computational method to analyze the spatial morphology of cells and tissues beyond standard microscopy. While AI shows great promise when combined with clinical, laboratory, molecular, and imaging data, its broad application in the clinical setting is constrained by issues such as heterogeneous databases, insufficient multicenter validation, poor model interpretability, and inadequate reporting. Going forward, there needs to be standardization of human databases, explainable AI, prospective validation, and federated learning that protects patient privacy.

Keywords: Hematologic disorders; Artificial intelligence (AI); Machine learning (ML); Digital hematology; Precision medicine; 3D morphologic fingerprinting; Leukemia; Sickle cell disease (SCD).

Received: May 21, 2026 **Revised: June 30, 2026** **Accepted: July 21 ,2026** **Published: August 12, 2026**

DOI: https://doi.org/10.64474/3107-6688.Vol2.Issue2.6

https://ddmd.nknpub.com/1/issue/archive

1. INTRODUCTION

Hematological diseases involve disorders of red cells, white cells, platelets, blood clotting factors, bone marrow, lymphoid tissue, and the genetic programs that control hematopoiesis. They manifest themselves through a variety of conditions including hereditary diseases like SCD, thalassemia, and hemophilia as well as acquired diseases like anemia, thrombocytopenia, eosinophilia, myelodysplastic disorders, leukemia, and lymphoma[1]. While each disease has a different mechanism, there are some common diagnostic considerations in the manifestation of the disease which include heterogeneity of disease presentation, interpretation of morphology with laboratory and molecular tests, and management based on risk stratification as opposed to diagnosis alone. Modern-day hematology needs an interdisciplinary approach of pathogenesis, etiology, epidemiology, radiology, cytology, genomics, and outcomes.

Pathogenesis is a better word to use compared to pathogens in this case since the diseases mentioned above are not caused by infections. The diseases develop due to different factors such as genetics, somatic mutation, deregulation of immunity, deficiency of nutrition, marrow failure, exposure to different elements, or a combination of any of the above[2]. While infection can influence development, it is not the primary cause of all diseases.

The relevance of AI and ML is due to the fact that the field of hematology has highly structured and rich in imagery data. Complete blood counts, differential blood counts, peripheral blood smear, bone marrow aspirate and biopsy, flow cytometry analysis, cytogenetic profile, sequencing data, treatment history, and survival data can be analyzed together. While deep learning can detect patterns in morphological structures, conventional ML can combine clinical and laboratory parameters[3]. However, it is not enough for clinical implementation just to demonstrate good results.

1.1 Background and Context

Traditional hematological diagnostics involve hematological indices, morphological analysis of cells, bone marrow study, immunophenotyping, cytogenetics, molecular diagnostics, and clinical aspects; hence the method is accurate but prone to interobserver variability, overload, and lack of specialists[4]. AI plays the role of the supporting technology that standardizes analysis, prioritizes abnormalities, and combines multivariate clinical information instead of displacing hematologists. In this setting, 3D fingerprinting means computational representation of 3D characteristics of the cells, tissues, and molecules, such as reconstructed bone marrow architecture, volumetric cell morphology, nucleus structure, spatial interactions between the cells, and combined immunophenotypic or molecular information.

1.2 Objectives of the Review

Aim of the study is as below:

- To integrate human-derived data regarding the pathogenesis, etiology, and epidemiology of the selected hematological disorders.
- To assess their diagnostic and precision medicine needs.
- To consider the use of AI and ML for the analysis of blood smears, marrow pathology, genomics, diagnosis, and treatment.
- To determine the possible use of 3D morphologic and molecular fingerprinting.
- To determine areas for future research not based on animal models.

1.3 Importance of the Topic

Importance of the topic lies in the fact that the chosen diseases cause considerable amounts of morbidity, transfusion dependency, bleeding, thrombotic events, organ injury, infections, toxicity from medications, and mortality[5]. The burden of disease varies among different regions and populations. At the same time, the availability of testing and diagnostics is also unequal. The use of proper AI can help to streamline these processes; however, if used incorrectly, the AI can contribute to the problem of inequality. The review is important in distinguishing biological mechanisms, diagnostic usefulness, technical viability, and clinical evidence.

2. HEMATOLOGIC DISORDERS: PATHOGENESIS, ETIOLOGY, EPIDEMIOLOGY, AND CLINICAL CHARACTERISTICS

Hematologic disorders are a collection of diverse diseases of blood involving red blood cells, white blood cells, platelets, the process of coagulation, and bone marrow. Despite each disease having a unique biochemical basis and presentation, diagnosis and management are not possible without a holistic approach combining clinical evaluation, laboratory tests, imaging, molecular analysis, and even AI-assisted methods[6]. Below is an overview of hematologic disorders discussed in this study.



Figure 1. Major pathophysiological mechanisms of sickle cell disease.

- **Sickle Cell Disease (SCD):** SCD is an inheritable hemoglobinopathy resulting from pathogenic mutations of HBB genes, which encode for hemoglobin S. Hemoglobin S polymerization occurs when the cells lack oxygen, resulting in the formation of sickle red blood cells, hemolytic anemia, endothelial dysfunction, inflammation, vaso-occlusion, and multi-organ failure[7]. The intensity of the disease is dependent on the genetic modifiers, the presence of fetal hemoglobin, and proper adherence to treatment and health care. AI-enabled predictive models are emerging based on longitudinal data of clinical, lab and imaging data.
- **Thalassemia:** Thalassemia is a genetic disorder that is caused by decreased production of either α- or β-globin chains leading to poor erythropoiesis, chronic anemia, hemolysis, bone marrow enlargement, and iron overload, especially among patients who require regular transfusions. The manifestation of the disease is influenced by the type of genetic mutations, mode of treatment using iron chelation, transfusion, and other clinical variables. AI and ML have exhibited great potential in thalassemia screening, interpretation of blood smears, prediction of iron overload, and transfusion management[8].
- **Leukemia:** Leukemia consists of acute and chronic cancers developing from either myeloid or lymphoid cells and occurs due to mutations in genes and chromosomes, exposure to the environment, and age-associated clonal evolution. The current diagnostic approaches combine morphology, immunophenotyping, cytogenetics, and molecular diagnostics for accurate classification of the disease and proper treatment choices. Deep learning and computer vision algorithms have shown high efficiency in automatic diagnosis and classification of leukemia based on peripheral blood smear and bone marrow images.
- **Lymphoma:** Lymphoma refers to a diverse set of cancers that are caused by B-cells, T-cells, and natural killer cells, which include Hodgkin's lymphoma and non-Hodgkin lymphoma, occurring due to an intricate relationship among changes in genetics, immune systems, viruses, and tumors' microenvironment[9]. It needs histopathology, immuno-histopathology, flow cytometry, and molecular pathology for proper diagnosis. AI -based digital pathology is gradually helping in lymph node segmentation, tumor-cell detection, subtype classification, microenvironment analysis, and prognostication.
- **Myelodysplastic Syndromes (MDS):** Myelodysplastic syndromes represent clonal bone marrow diseases defined by ineffective blood cell production, cytopenia, dysplasia, genetic aberrations, and variable evolution into acute myeloid leukemia. Clinical prognosis is based on cytogenetic risk assessment, presence of mutations, blast count, and patients' features. ML algorithms are being tested for their potential in

diagnostics, prognostics, survival prediction, and therapy choices tailored for each individual patient by analyzing complex data sets.

- **Hemophilia:** Hemophilia A and B are genetic disorders characterized by a lack of coagulation factor VIII or IX and poor clotting, leading to frequent spontaneous or trauma-induced bleeds. Severity of the disease depends on the level of activity of the clotting factors, presence of inhibitors, compliance with treatment, and the state of joints. Currently, AI-based prediction models are increasingly used to assess the risk of bleeding, tailor factor prophylaxis, forecast inhibitor development, and plan treatment[10].
- **Anemia:** Anemia is a medical condition where there is low hemoglobin content or low number of red blood cells due to defective erythropoiesis, nutritional factors, bleeding, destruction of red blood cells, inflammation, kidney diseases, or genetic blood disorders. Due to the fact that several causes can be present together, diagnosis is made through the interpretation of various factors such as laboratory tests, biochemistry, and the patient's history. AI programs are being developed to help diagnose types of anemia and make diagnoses easier for doctors[11].
- **Eosinophilia and Thrombocytopenia:** Both eosinophilia and thrombocytopenia represent hematological disorders that have a wide range of differential diagnoses such as allergies, parasitic infections, autoimmune disorders, drug reactions, bone marrow diseases, platelet immune-mediated destruction, and malignancies of hematologic nature. As abnormal counts do not allow diagnosing the disease, additional measures should be taken including peripheral smear, lab data, patient history, molecular information, and organs analysis. The use of AI algorithms would help to increase diagnostic accuracy because of the incorporation of temporal trends in lab data, clinical information, imaging, and molecular aspects.

3. AI, MACHINE LEARNING, AND DIGITAL HEMATOLOGY

AI in hematology includes rule-based systems, machine learning, deep learning, NLP, and multi-modal data fusion, with successful use cases in digital cytology, cell detection, image classification, genomic analysis, and laboratory data integration[12]. The successful workflow of AI in clinical practice begins with setting a well-defined goal like screening, classification of disease, prediction of prognosis, response to therapy, and patient monitoring, with the help of patient level datasets and appropriate clinical reference standards. In order to ensure the clinical relevance of AI in practice, data needs to be stratified by patient, hospital, and time, and the model needs to be evaluated based on the following parameters.

3.1 Image-Based Detection and Classification

Digital imagery of peripheral blood and bone marrow smears is perhaps one of the most well-studied uses of AI technology in the field of hematology[13]. CNNs and other types of deep

learning systems are capable of recognizing complex morphologic features such as cell nucleus morphology, chromatin distribution, cytoplasm texture, granularity, cell size, and spatial relationships between cells. There have been a great many examples of high success in detecting and classifying leukemia, especially acute lymphoblastic leukemia, from digital imagery of peripheral blood smears and bone marrow smears[14].

Even with these advancements, mere microscopy images often do not contain enough data to arrive at a proper diagnosis. Classification of blood cancers usually necessitates the combination of the results from morphology, immunophenotype analysis, flow cytometry, cytogenetics, molecular genetics, and clinical presentation. As such, an AI system based on image recognition should be considered more of a supplementary diagnostic aid to hematologists and not a replacement to thorough testing[15]. Staining differences, variations in scanning technology, poor slide preparation, and the absence of rare cells in the sample can greatly affect the performance of the model.



Figure 2. AI-based workflow for automated blood cell image classification.

Future image analysis algorithms need to take into account not only better accuracy of classification but also robustness across various institutes and imaging modalities. Uniform acquisition standards of images, validation studies on various patient populations, as well as inclusion of image analysis into digital pathology workflow, will be necessary to make these tools a part of standard clinical practice[16]. Inclusion of other types of data apart from image analysis is likely to improve accuracy further.

3.2 Structured Data, Genomics, and Multimodal Fusion

Various ML algorithms such as logistic regression, random forests, support vector machines, gradient boosting, and fuzzy inference system have been employed on structured data within hematology. They allow for the analysis of complete blood count data, coagulation data, demographic variables, biochemical data, treatment history, and biomarker data to be able to make predictions about diseases, risk, and therapies[17]. These approaches tend to be more interpretable than deep learning approaches and function well when there are fewer amounts of data available or when there are structured clinical variables.

AI is also being utilized in conjunction with genomics and multi-omics to find disease-related mutations, prioritize genetic variants, identify molecular markers, and classify diseases. This is especially important in hematological malignancies such as leukemia, lymphoma, and myelodysplasia because of the significance of genomic alterations in prognosis and therapy. The use of molecular and clinical variables allows for proper patient stratification.

The highest future possibilities lie with multimodal systems, which would be capable of incorporating multiple and different data sources within a single diagnostic system. Such systems could include leukemia diagnostic tools, which could incorporate computerized smear images, flow cytometry, cytogenetics, genomic sequencing, demographic and laboratory data, along with SCD, where genetic data, laboratory data over time, associated complications, and organ function data would all be incorporated into the system[18].

3.3 Explainability, Calibration, and Clinical Oversight

Explanation is critical to establishing trust among clinicians in order to implement the use of AI technology safely in the field of hematology. The method used to explain must match the task being performed. For image-based systems, an explanation would require the areas of the cell involved in the decision to be pointed out, while a structured data system would indicate the factors in the lab data and clinical data which influenced the prediction. The genomic AI system should disclose the variants, biological processes, and biological evidence used[19].

It is crucial as well since accurate probability estimates affect confidence in the diagnosis and treatment options. The model can rank patients by their risk of having a disease even though it gives false probability estimates that can affect clinical decision-making[20]. It means that continuous calibration checks, evaluation of performance in specific subgroups, and calculation of uncertainty become mandatory parts of AI validation process before it is put into practice[21].

The successful application of the AI algorithm requires further clinical supervision after its launch. Clinics have to evaluate constantly the performance of the system, spot any changes in its performance, keep the audit logs, and update the algorithms with new clinical data from

time to time. AI-based predictions have to be evaluated within the clinical context and help hematologists and hematopathologists to make a decision[22].

Table 1. Comparative Human-Centered Profile of Selected Hematologic Disorders

Disorder	Core Mechanism	Key Human Data	AI/ML Application	Major Challenge	Clinical Need
SCD	HbS polymerization, vaso-occlusion	Genotype, CBC, organ function	Risk prediction, monitoring	Population bias	Prospective validation
Thalassemia	Globin-chain imbalance	CBC, Hb analysis, genotype	Carrier screening, treatment planning	Iron-deficiency overlap	External validation
Leukemia	Clonal hematopoietic proliferation	Smear, marrow, genomics	Detection, classification	Data leakage	Multimodal validation
Lymphoma	Clonal lymphoid malignancy	Histology, IHC, molecular data	Subtype classification	Site variability	Multicenter validation
Myelodysplastic Syndromes	Ineffective hematopoiesis	Cytopenias, marrow, genetics	Risk stratification	Disease overlap	Comparison with standard scores
Hemophilia	Factor VIII/IX deficiency	Factor levels, genotype	Bleeding prediction	Small datasets	Multicenter evaluation
Anemia	Reduced RBC production or loss	CBC, iron profile, reticulocytes	Etiology prediction	Mixed causes	Confirmatory testing

Eosinophilia	Reactive/clonal eosinophilia	Smear, organ assessment	Differential diagnosis	Rare disorders	Safety-based evaluation
Thrombocytopenia	Reduced production/destruction	Platelets, smear, coagulation	Diagnostic support	False-positive counts	Rapid confirmation

4. 3D MORPHOLOGIC AND MOLECULAR FINGERPRINTING

3D fingerprinting is an advancement of the traditional two-dimensional approach in that it incorporates the volume and spatial arrangement of cells and tissues to create unique disease-related fingerprints[23]. By means of techniques like z-stack microscopy, confocal imaging, optical sections, and 3D imaging, it is capable of extracting characteristics including cell morphology, nuclear structure, topography of the tissue, cellular neighborhood, blasts grouping, fibrosis, and localization of molecules[24]. AI uses these characteristics to create disease signatures at the level of individual patients to assist in the classification, prognostic information and treatment tracking of conditions such as myelodysplastic syndrome, lymphoma, leukemia, and SCD. But it needs to be validated along with two-dimensional approaches[25].



Figure 3. Representative erythrocyte morphologic phenotypes for AI-assisted hematologic analysis.

4.1 Human-Derived Samples and Validation

Smears of human blood, aspiration from bone marrow, biopsy from bone marrow, tissue from lymph nodes, flow cytometry, and molecular analysis from patients are all part of the dataset which should make up the backbone for AI models within hematology[26]. The validation process should maintain the independence of the patients through making sure no sample from a patient is included in both the training and test datasets[27]. The AI models should be validated using data from other laboratories, scanners, staining methods, disease stages, age groups, and demographics to increase robustness. In cases where there are longitudinal studies, the temporal order of the samples should be considered[28].

The reference test needs to be similar to routine medical practice. In case of leukemia and lymphoma, a patient's diagnosis requires morphological analysis, immunophenotyping, cytogenetic testing, molecular changes, and clinical information instead of only one of these methods. Likewise, in myelodysplastic syndromes, there is a need for a thorough analysis of cytopenias, bone marrow morphology, cytogenetic abnormalities, and mutations. In case of anemia, thrombocytopenia, and eosinophilia, an AI model should determine the etiology of the condition or suggest further diagnostic actions[29].

In addition to the technical validation of the AI models, future research should focus on whether the use of the AI models enhances the process and speed of diagnosis as well as patient outcomes. Prospective multicenter validation, structured reporting methods, and clear performance measurements are necessary before deploying in clinical practice[30]. Monitoring of model performance after the implementation is also critical.

4.2 Privacy, Fairness, and Data Governance

Given that hematology data may include sensitive clinical information, genetic profiling data, digital images from pathology, and longitudinal health data that increases the chance of patient identification, data governance needs to formulate policies on obtaining consent from patients, securing the data, controlling access to the data, model reuse, and using the data for secondary research purposes[31]. Privacy-preserving approaches like federated learning, encryption in computations, and data sharing platforms can help facilitate multi-center research without requiring patient data to be transferred.

The idea of fairness must be taken into account during the development and assessment of any ML model[32]. It is critical to evaluate the performance of the ML algorithm among patients with a diverse set of demographics including age, sex, ethnicity, geographic location, socio-economic status, whether or not pregnant, comorbidity, and type of laboratory platform whenever applicable. Such an issue is especially important for diseases like sickle cell anemia and thalassemia.

Clear governance and explainability of AI models are equally important in keeping clinicians' trust and implementing the models responsibly within the clinical context. Healthcare

organizations need to conduct auditing on a regular basis to detect model drift, biases, and decrease in the model's performance. Documentation of how the model was developed, validated, and its limitations and intended use in the clinical setting needs to be transparent[33].

Table 2. Selected Literature and Its Contribution to AI-Enabled Hematology

Author(s) & Year	Study Focus	Key Findings	Contribution to AI-Enabled Hematology
Stepanov et al. (2024)[34]	Overview of blood diseases and systemic manifestations	Summarized the clinical characteristics, diagnosis, and multidisciplinary management of major hematologic disorders.	Provides comprehensive clinical knowledge that supports AI-assisted diagnosis and decision-making frameworks.
Sundd et al. (2019)[35]	Pathophysiology of SCD	Explained the roles of hemolysis, inflammation, endothelial dysfunction, and vaso-occlusion in disease progression.	Identifies key biological markers that can be incorporated into AI models for risk prediction and disease monitoring.
Tebbi (2022)[36]	Comprehensive review of SCD	Reviewed genetics, clinical presentation, diagnosis, and current therapeutic approaches.	Supports the development of AI systems for early diagnosis, patient stratification, and personalized management of SCD.
Tsagiopoulou & Gut (2024)[37]	ML and multi-omics in chronic lymphocytic leukemia	Discussed integration of ML with multi-omics data for precision medicine and prognostic prediction.	Demonstrates the value of AI-driven multi-omics analysis for personalized diagnosis and treatment of hematologic malignancies.
Wang et al. (2024)[38]	AI in hematologic disease diagnosis and treatment	Reviewed AI applications in diagnosis, disease classification, prognosis, and clinical decision	Highlights the broad clinical potential of AI for improving diagnostic accuracy,

		support across hematologic disorders.	treatment optimization, and precision hematology.

5. DISCUSSION

Although the reviewed hematologic conditions have different biological underpinnings, the key feature common to all of them is the requirement for a comprehensive diagnosis approach. From the findings of the current review, it is clear that the use of AI is most valuable in cases when the algorithm uses clinical, laboratory, imaging, and molecular data for making decisions regarding diagnosis, prognosis, and treatment instead of relying solely on one data source[39]. Image-based algorithms are helpful in screening and preliminary classification, while final diagnosis should be done using molecular and clinical data; structured-data algorithms should undergo validation in diverse populations in order to achieve generalizability. Additionally, the issues of rare diseases and class imbalance should be considered, making multicenter validation and accurate uncertainty estimation critical. Finally, the 3D morphologic and molecular fingerprinting technique is promising but needs further research and implementation[40].

5.1 Interpretation and Analysis of Findings

AI needs to be considered an evidence integration layer. For sickle cell anemia, AI can predict high-risk trajectories; for thalassemia, carrier detection and iron overload treatment; for leukemia and lymphoma, help morphology, diagnosis, and prognostics; for MDS, facilitate risk modeling; for hemophilia, facilitate personalized prophylaxis; and for anemias, eosinophilia, and thrombocytopenia, help etiologic triage. The value is not in the replacement of the specialized diagnosis but in avoiding delays, standardizing measures, and rendering complicated evidences more accessible.

5.2 Implications and Significance

It should be noted from the results of this review that in the future the management of hematological disorders would involve the incorporation of the use of AI, machine learning, digital pathology, genomics profiling, and computational imaging into traditional medicine practice. The role of AI is not to substitute hematologists but rather provide assistance in terms of improving diagnosis, disease classification, risk stratification, and providing personalized therapy through the integration of various forms of information. This review also emphasizes the potential of the use of 3D fingerprinting to augment traditional microscopy due to more detailed spatial description of hematological tissues. The combination of these techniques and explainable AI together with validated human data might enhance the effectiveness of disease phenotyping and precision medicine.

5.3 Research Gaps and Limitations

The most common research challenges that need to be addressed are small dataset size and single-center collection, inconsistency in data annotation, retrospective design, insufficient external validation, inadequate calibration information, inadequate subgroup analysis, and the lack of prospective studies evaluating the impact of the AI application on patient care. Very often AI-based algorithms use selected images instead of comprehensive data from patients' medical histories, and show no substantial benefits for clinical decision-making. The above-mentioned issues have particular importance regarding rare hematologic conditions and minority groups. This review is limited by its focus on different diseases and selected literature, including review papers along with primary studies. Also, the animal-model studies were purposefully excluded, considering the human-centered approach of the study, whereas 3D fingerprinting serves as an algorithmic technique only.

5.4 Future Research Directions

Research in the future should target the creation of large-scale human cohorts with data combining morphology of blood and bone marrow, flow cytometry, cytogenetic, genomic sequencing, treatments, and outcomes, thus facilitating powerful patient-specific AI models. Research in the future should highlight prospective validation, calibration of models, uncertainty quantification, and privacy-preserving cooperative learning, especially when rare hematology diseases are concerned. Besides, 3D analysis should tackle clinically important problems, including classification of myelodysplastic syndromes and improved diagnosis of leukemia and SCD using spatial properties of cells. Furthermore, there should be an increased focus on interpretable AI models, standardization, and low-cost digital diagnostics.

6. CONCLUSION

SCD, thalassemia, leukemia, lymphomas, myelodysplasia, hemophilia, anemia, eosinophilia, and thrombocytopenia are different yet interrelated fields of study within hematology. Each requires an integrated approach considering the pathogenesis, causality, epidemiology, morphology, lab findings, molecular features, and clinical presentation. AI and ML can enhance this integration by means of imaging analysis, genomics, predicting risk, and multimodal decision support. 3D morphological and molecular fingerprinting might be another way to account for cell and spatial heterogeneity, although its clinical relevance is yet to be proven via standardized human research. The most promising path towards translation is human-centered, explainable, validated, fair, and clinically supervised.

REFERENCES

1. Almbaidin, H., Abeden, Z., Alhawamdeh, M., Nazman, H. N. M., Hamdani, H. Y., Yusoff, N. M., & Isa, A. (2024). Application of artificial intelligence in the diagnosis of haematological disorders. Biomedical Research and Therapy, 11(12), 6989-7002.

2. Bispo, J. A. B., Pinheiro, P. S., & Kobetz, E. K. (2020). Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harbor perspectives in medicine, 10(6), a034819.
3. Biswas, M. D. (2025). Pediatric Hematopathology: Bone Marrow Disorders, Leukemias, Lymphomas, and Molecular Diagnostics. Birupaksha, Pediatric Hematopathology: Bone Marrow Disorders, Leukemias, Lymphomas, and Molecular Diagnostics (September 29, 2025). Biswas, B.
4. Bukhari, M., Yasmin, S., Sammad, S., & Abd El-Latif, A. A. (2022). A deep learning framework for leukemia cancer detection in microscopic blood samples using squeeze and excitation learning. Mathematical Problems in Engineering, 2022(1), 2801227.
5. Camicia, R., Winkler, H. C., & Hassa, P. O. (2015). Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. Molecular cancer, 14(1), 207.
6. Chaparro, C. M., & Suchdev, P. S. (2019). Anemia epidemiology, pathophysiology, and etiology in low-and middle-income countries. Annals of the new York Academy of Sciences, 1450(1), 15-31.
7. Colombatti, R., Birkegård, C., & Medici, M. (2022). PB2215: global epidemiology of sickle cell disease: a systematic literature review. Hemasphere, 6, 2085-2086.
8. Das, P. K., Diya, V. A., Meher, S., Panda, R., & Abraham, A. (2022). A systematic review on recent advancements in deep and machine learning based detection and classification of acute lymphoblastic leukemia. IEEE access, 10, 81741-81763.
9. El Alaoui, Y., Elomri, A., Qaraqe, M., Padmanabhan, R., Yasin Taha, R., El Omri, H., ... & Aboumarzouk, O. (2022). A review of artificial intelligence applications in hematology management: current practices and future prospects. Journal of Medical Internet Research, 24(7), e36490.
10. Fox, T. A., & Morris, E. C. (2022). Haematological Disease. In Medicine for Finals and Beyond (pp. 557-596). CRC Press.
11. Gaikwad, D., Mahale, V., & Gaikwad, A. (2024, February). A review on blood disease detection using artificial intelligence techniques. In 2024 IEEE International Conference on Big Data & Machine Learning (ICBDML) (pp. 21-26). IEEE.
12. Gedefaw, L., Liu, C. F., Ip, R. K. L., Tse, H. F., Yeung, M. H. Y., Yip, S. P., & Huang, C. L. (2023). Artificial intelligence-assisted diagnostic cytology and genomic testing for hematologic disorders. Cells, 12(13), 1755.
13. Ghaderzadeh, M., Asadi, F., Hosseini, A., Bashash, D., Abolghasemi, H., & Roshanpour, A. (2021). Machine learning in detection and classification of leukemia using smear blood images: a systematic review. Scientific programming, 2021(1), 9933481.
14. Ibrahim, M., Abbas, S., Fatima, A., Ghazal, T. M., Saleem, M., Alharbi, M., ... & Elmitwally, N. (2024). Fuzzy-Based Fusion Model for β-Thalassemia Carriers

Prediction Using Machine Learning Technique. Advances in Fuzzy Systems, 2024(1), 4468842.

15. Inusa, B. P., Hsu, L. L., Kohli, N., Patel, A., Ominu-Evbota, K., Anie, K. A., & Atoyebi, W. (2019). Sickle cell disease—genetics, pathophysiology, clinical presentation and treatment. International journal of neonatal screening, 5(2), 20.

16. Kansal, R. (2016). Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification. Cancer biology & medicine, 13(1), 41-54.

17. Kato, G. J., Steinberg, M. H., & Gladwin, M. T. (2017). Intravascular hemolysis and the pathophysiology of sickle cell disease. The Journal of clinical investigation, 127(3), 750-760.

18. Kovalyova, O., Pasiieshvili, L., Frolova, T., Andrusha, A., Shapkin, V., & Ivanchenko, S. (2021). Syndromes and diseases of the blood system: textbook.

19. Lizarralde-Iragorri, M. A., & Shet, A. S. (2020). Sickle cell disease: a paradigm for venous thrombosis pathophysiology. International journal of molecular sciences, 21(15), 5279.

20. Mavridou, D., Psatha, K., & Aivaliotis, M. (2021). Proteomics and drug repurposing in CLL towards precision medicine. Cancers, 13(14), 3391.

21. McCord, C., & Johnson, L. (2017). Oral manifestations of hematologic disease. Atlas of the Oral and Maxillofacial Surgery Clinics of North America, 25(2), 149-162.

22. Moia, R., Patriarca, A., Schipani, M., Ferri, V., Favini, C., Sagiraju, S., ... & Gaidano, G. (2020). Precision medicine management of chronic lymphocytic leukemia. Cancers, 12(3), 642.

23. Nazha, A., Elemento, O., Ahuja, S., Lam, B., Miles, M., Shouval, R., ... & Haferlach, T. (2025). Artificial intelligence in hematology. Blood.

24. Obeagu, E. I. (2025). Revolutionizing hematological disorder diagnosis: unraveling the role of artificial intelligence. Annals of Medicine and Surgery, 87(6), 3445-3457.

25. Obstfeld, A. E. (2023). Hematology and machine learning. The Journal of Applied Laboratory Medicine, 8(1), 129-144.

26. Prasad, V., & Gale, R. P. (2016). Precision medicine in acute myeloid leukemia: Hope, hype or both?. Leukemia Research, 48, 73-77.

27. Rastogi, P., Khanna, K., & Singh, V. (2022). LeuFeatx: Deep learning–based feature extractor for the diagnosis of acute leukemia from microscopic images of peripheral blood smear. Computers in Biology and Medicine, 142, 105236.

28. Rezayi, S., Mohammadzadeh, N., Bouraghi, H., Saeedi, S., & Mohammadpour, A. (2021). Timely diagnosis of acute lymphoblastic leukemia using artificial intelligence-oriented deep learning methods. Computational Intelligence and Neuroscience, 2021(1), 5478157.

29. Rosenquist, R., Bernard, E., Erkers, T., Scott, D. W., Itzykson, R., Rousselot, P., ... & Smedby, K. E. (2023). Novel precision medicine approaches and treatment strategies in hematological malignancies. Journal of Internal Medicine, 294(4), 413-436.
30. Sadiq, I. Z., Abubakar, F. S., Usman, H. S., Abdullahi, A. D., Ibrahim, B., Kastayal, B. S., ... & Hassan, H. A. (2024). Thalassemia: Pathophysiology, diagnosis, and advances in treatment. Thalassemia Reports, 14(4), 81-102.
31. Sankar, V., & Villa, A. (2021). Hematologic diseases. Burket's oral medicine, 627-664.
32. Simeon, V., Todoerti, K., La Rocca, F., Caivano, A., Trino, S., Lionetti, M., ... & Musto, P. (2015). Molecular classification and pharmacogenetics of primary plasma cell leukemia: an initial approach toward precision medicine. International journal of molecular sciences, 16(8), 17514-17534.
33. Singh, R., Shaik, S., Negi, B. S., Rajguru, J. P., Patil, P. B., Parihar, A. S., & Sharma, U. (2020). Non-Hodgkin's lymphoma: A review. Journal of family medicine and primary care, 9(4), 1834-1840.
34. Stepanov, A., Radocha, J., & Matuskova, V. (2024). Blood Diseases. In Ocular Manifestations of Systemic Diseases (pp. 23-77). Cham: Springer International Publishing.
35. Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019). Pathophysiology of sickle cell disease. Annual review of pathology: mechanisms of disease, 14(1), 263-292.
36. Tebbi, C. K. (2022). Sickle cell disease, a review. Hemato, 3(2), 341-366.
37. Tsagiopoulou, M., & Gut, I. G. (2024). Machine learning and multi-omics data in chronic lymphocytic leukemia: the future of precision medicine?. Frontiers in Genetics, 14, 1304661.
38. Wang, S. X., Huang, Z. F., Li, J., Wu, Y., Du, J., & Li, T. (2024). Optimization of diagnosis and treatment of hematological diseases via artificial intelligence. Frontiers in Medicine, 11, 1487234.
39. Wästerlid, T., Cavelier, L., Haferlach, C., Konopleva, M., Fröhling, S., Östling, P., ... & Smedby, K. E. (2022). Application of precision medicine in clinical routine in haematology—Challenges and opportunities. Journal of Internal Medicine, 292(2), 243-261.
40. Zhang, L., An, Z., Cui, L., Li, W., & Zhang, X. (2025). Research progress of artificial intelligence in the clinical diagnosis and treatment of hematological diseases. Chinese Science Bulletin, 70(12), 1819-1828.